vs
Astrana Health, Inc.（ASTH）与OPEN TEXT CORP（OTEX）财务数据对比。点击上方公司名可切换其他公司
OPEN TEXT CORP的季度营收约是Astrana Health, Inc.的1.3倍（$1.3B vs $950.5M），OPEN TEXT CORP净利率更高（13.5% vs 0.7%，领先12.8%），Astrana Health, Inc.同比增速更快（42.9% vs 2.2%），OPEN TEXT CORP自由现金流更多（$305.0M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs -3.0%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
Open Text Corporation是全球知名的跨国软件企业，专注于信息管理类软件的研发与销售，业务覆盖全球众多国家和地区，可为各行业客户提供成熟的信息管理解决方案，助力企业高效管理数据资产，推进数字化转型落地。
ASTH vs OTEX — 直观对比
营收规模更大
OTEX
是对方的1.3倍
$950.5M
营收增速更快
ASTH
高出40.6%
2.2%
净利率更高
OTEX
高出12.8%
0.7%
自由现金流更多
OTEX
多$310.9M
$-6.0M
两年增速更快
ASTH
近两年复合增速
-3.0%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $1.3B |
| 净利润 | $6.6M | $172.7M |
| 毛利率 | — | 73.1% |
| 营业利润率 | 1.9% | 15.7% |
| 净利率 | 0.7% | 13.5% |
| 营收同比 | 42.9% | 2.2% |
| 净利润同比 | 184.4% | — |
| 每股收益（稀释后） | $0.12 | $0.70 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHOTEX
| Q1 26 | — | $1.3B | ||
| Q4 25 | $950.5M | $1.3B | ||
| Q3 25 | $956.0M | $1.3B | ||
| Q2 25 | $654.8M | $1.3B | ||
| Q1 25 | $620.4M | $1.3B | ||
| Q4 24 | $665.2M | $1.3B | ||
| Q3 24 | $478.7M | $1.3B | ||
| Q2 24 | $486.3M | $1.4B |
净利润ASTHOTEX
| Q1 26 | — | $172.7M | ||
| Q4 25 | $6.6M | $168.1M | ||
| Q3 25 | $373.0K | $146.6M | ||
| Q2 25 | $9.4M | $28.8M | ||
| Q1 25 | $6.7M | $92.8M | ||
| Q4 24 | $-7.8M | $229.9M | ||
| Q3 24 | $16.1M | $84.4M | ||
| Q2 24 | $19.2M | $248.2M |
毛利率ASTHOTEX
| Q1 26 | — | 73.1% | ||
| Q4 25 | — | 74.0% | ||
| Q3 25 | — | 72.8% | ||
| Q2 25 | — | 72.3% | ||
| Q1 25 | — | 71.6% | ||
| Q4 24 | — | 73.3% | ||
| Q3 24 | — | 71.7% | ||
| Q2 24 | — | 72.5% |
营业利润率ASTHOTEX
| Q1 26 | — | 15.7% | ||
| Q4 25 | 1.9% | 22.0% | ||
| Q3 25 | 2.0% | 21.0% | ||
| Q2 25 | 3.1% | 13.9% | ||
| Q1 25 | 3.3% | 16.7% | ||
| Q4 24 | 0.1% | 22.2% | ||
| Q3 24 | 5.9% | 16.3% | ||
| Q2 24 | 6.2% | 14.2% |
净利率ASTHOTEX
| Q1 26 | — | 13.5% | ||
| Q4 25 | 0.7% | 12.7% | ||
| Q3 25 | 0.0% | 11.4% | ||
| Q2 25 | 1.4% | 2.2% | ||
| Q1 25 | 1.1% | 7.4% | ||
| Q4 24 | -1.2% | 17.2% | ||
| Q3 24 | 3.4% | 6.6% | ||
| Q2 24 | 3.9% | 18.2% |
每股收益（稀释后）ASTHOTEX
| Q1 26 | — | $0.70 | ||
| Q4 25 | $0.12 | $0.66 | ||
| Q3 25 | $0.01 | $0.58 | ||
| Q2 25 | $0.19 | $0.11 | ||
| Q1 25 | $0.14 | $0.35 | ||
| Q4 24 | $-0.14 | $0.87 | ||
| Q3 24 | $0.33 | $0.32 | ||
| Q2 24 | $0.40 | $0.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $1.3B |
| 总债务越低越好 | — | $6.2B |
| 股东权益账面价值 | $779.3M | $4.0B |
| 总资产 | $2.2B | $13.3B |
| 负债/权益比越低杠杆越低 | — | 1.57× |
8季度趋势，按日历期对齐
现金及短期投资ASTHOTEX
| Q1 26 | — | $1.3B | ||
| Q4 25 | $429.5M | $1.3B | ||
| Q3 25 | $463.4M | $1.1B | ||
| Q2 25 | $342.1M | $1.2B | ||
| Q1 25 | $260.9M | $1.3B | ||
| Q4 24 | $290.8M | $1.1B | ||
| Q3 24 | $350.3M | $1.0B | ||
| Q2 24 | $327.7M | $1.3B |
总债务ASTHOTEX
| Q1 26 | — | $6.2B | ||
| Q4 25 | — | $6.4B | ||
| Q3 25 | — | $6.4B | ||
| Q2 25 | — | $6.4B | ||
| Q1 25 | — | $6.4B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.4B |
股东权益ASTHOTEX
| Q1 26 | — | $4.0B | ||
| Q4 25 | $779.3M | $4.0B | ||
| Q3 25 | $775.5M | $4.0B | ||
| Q2 25 | $765.5M | $3.9B | ||
| Q1 25 | $745.4M | $4.1B | ||
| Q4 24 | $712.7M | $4.2B | ||
| Q3 24 | $704.6M | $4.1B | ||
| Q2 24 | $678.9M | $4.2B |
总资产ASTHOTEX
| Q1 26 | — | $13.3B | ||
| Q4 25 | $2.2B | $13.6B | ||
| Q3 25 | $2.2B | $13.5B | ||
| Q2 25 | $1.4B | $13.8B | ||
| Q1 25 | $1.3B | $13.8B | ||
| Q4 24 | $1.4B | $13.7B | ||
| Q3 24 | $1.3B | $13.8B | ||
| Q2 24 | $1.3B | $14.2B |
负债/权益比ASTHOTEX
| Q1 26 | — | 1.57× | ||
| Q4 25 | — | 1.58× | ||
| Q3 25 | — | 1.61× | ||
| Q2 25 | — | 1.62× | ||
| Q1 25 | — | 1.55× | ||
| Q4 24 | — | 1.51× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.52× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $354.6M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $305.0M |
| 自由现金流率自由现金流/营收 | -0.6% | 23.8% |
| 资本支出强度资本支出/营收 | 0.3% | 3.9% |
| 现金转化率经营现金流/净利润 | -0.44× | 2.05× |
| 过去12个月自由现金流最近4个季度 | $104.5M | $809.6M |
8季度趋势，按日历期对齐
经营现金流ASTHOTEX
| Q1 26 | — | $354.6M | ||
| Q4 25 | $-2.9M | $318.7M | ||
| Q3 25 | $10.0M | $147.8M | ||
| Q2 25 | $90.9M | $158.2M | ||
| Q1 25 | $16.6M | $402.2M | ||
| Q4 24 | $-10.9M | $348.0M | ||
| Q3 24 | $34.0M | $-77.8M | ||
| Q2 24 | $23.2M | $185.2M |
自由现金流ASTHOTEX
| Q1 26 | — | $305.0M | ||
| Q4 25 | $-6.0M | $279.4M | ||
| Q3 25 | $7.4M | $101.2M | ||
| Q2 25 | $89.5M | $124.0M | ||
| Q1 25 | $13.6M | $373.8M | ||
| Q4 24 | $-13.5M | $306.7M | ||
| Q3 24 | $31.7M | $-117.1M | ||
| Q2 24 | $20.4M | $145.2M |
自由现金流率ASTHOTEX
| Q1 26 | — | 23.8% | ||
| Q4 25 | -0.6% | 21.1% | ||
| Q3 25 | 0.8% | 7.9% | ||
| Q2 25 | 13.7% | 9.5% | ||
| Q1 25 | 2.2% | 29.8% | ||
| Q4 24 | -2.0% | 23.0% | ||
| Q3 24 | 6.6% | -9.2% | ||
| Q2 24 | 4.2% | 10.7% |
资本支出强度ASTHOTEX
| Q1 26 | — | 3.9% | ||
| Q4 25 | 0.3% | 3.0% | ||
| Q3 25 | 0.3% | 3.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.5% | 2.3% | ||
| Q4 24 | 0.4% | 3.1% | ||
| Q3 24 | 0.5% | 3.1% | ||
| Q2 24 | 0.6% | 2.9% |
现金转化率ASTHOTEX
| Q1 26 | — | 2.05× | ||
| Q4 25 | -0.44× | 1.90× | ||
| Q3 25 | 26.69× | 1.01× | ||
| Q2 25 | 9.65× | 5.49× | ||
| Q1 25 | 2.48× | 4.33× | ||
| Q4 24 | — | 1.51× | ||
| Q3 24 | 2.11× | -0.92× | ||
| Q2 24 | 1.21× | 0.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
OTEX
| Customer support | $564.8M | 44% |
| Cloud services and subscriptions | $492.9M | 38% |
| License | $145.1M | 11% |
| Professional service and other | $79.6M | 6% |
